Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia.

Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL), since large quantities of CD33 are commonly expressed on the surface of APL cells. The present study reported two cases with prominent disseminated intravascular coagulation (DIC), which was transiently observed following treatment with GO with relapsed/refractory APL. Very limited information exists regarding DIC occurring following GO, and its mechanism remains to be elucidated. In the present study, recombinant human soluble thrombomodulin was used for DIC treatment, and the patients recovered promptly. Since DIC is the most serious adverse event associated with GO treatment, elucidation of its mechanism and establishment of a treatment strategy are warranted.

Introduction

Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin (Ig)G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL), since large quantities of CD33 are commonly expressed on the surface of APL cells. Although several previous studies have reported successful results for the use of GO as APL therapy (1–8), no large clinical studies of GO for APL treatment have been performed. APL is characterized by fibrinolytic-type disseminated intravascular coagulation (DIC). The present study reported two patients who developed DIC following treatment with GO, although their coagulation profiles revealed no presence of DIC prior to the treatment. Since prominent DIC was transiently observed following treatment with GO, it may be an adverse event caused by GO. Very limited information exists regarding DIC occurring following treatment with GO (9), and its mechanism remains unclear. The present study used recombinant human soluble thrombomodulin (rTM) for the treatment of DIC, although rTM in combination with GO has not been previously reported, to the best of our knowledge. The present study reported on these two patients with relapsed/refractory APL who exhibited DIC following treatment with GO, receiving rTM therapy for DIC.

Case reports

Case 1

An 85-year-old man presented with pancytopenia in August 2011 at the First Department of Internal Medicine, Kansai Medical University (Osaka, Japan). A chromosome analysis revealed 46, XY, t(15;17) (q22;21), and APL was diagnosed. Treatment with all-trans retinoic acid (ATRA) and chemotherapy, including idarubicin (IDA), was administered, and hematological complete remission (CR) was attained in November 2011. The patient received maintenance chemotherapy, according to the PETHEMA LPA 2005 regimen (10), and achieved molecular CR in December 2011. The patient continued to receive ATRA until he developed interstitial pneumonia in April 2012. In October 2012, the patient had a molecular relapse and restarted ATRA, however, the disease was refractory. In December 2012, the patient received arsenic trioxide (ATO) and achieved a second CR. In October 2013, the patient had a third molecular relapse. A bone marrow smear revealed 1.8% APL cells. The mRNA of promyelocytic leukemia (PML)/retinoic acid receptor (RAR)α was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR; 1.8×104 copies/µg). The results of laboratory tests were as follows: Erythrocyte count, 3.93×1012/l; platelet count, 15.1×109/l; leukocyte count, 5.9×109/l (the leukocytes included 0% promyelocytes, 4.5% monocytes, 45.5% neutrophils and 34.5% lymphocytes). GO (9 mg/m2) was administered on days 1 and 15. The clinical course is shown in Fig. 1. Prominent DIC was transiently observed following the treatment. On day 4, the prothrombin time (PT) was 92.6%, the activated partial thromboplastin time (APTT) was 26.6 sec, the fibrinogen level was 391 g/l, the fibrin degradation product (FDP) level was 149.8 µg/ml and the fibrin degradation product D-dimer (FDP-DD) level was elevated to 92.6 µg/ml. Treatment with rTM was initiated. During this treatment, the FDP and FDP-DD levels gradually decreased. A reduction in the level of fibrinogen was not observed. GO was administered again on day 15. This caused a slight increase in FDP-DD levels, which promptly decreased. Molecular CR was confirmed on day 41.

Figure 1.

Clinical course of the patient in case 1. GO, gemtuzumab ozogamicin; PT, prothrombin time; WBC, white blood cell count; PLT, platelets; rTM, recombinant human soluble thrombomodulin; APTT, activated partial thromboplastin time; FDP, fibrin degradation product; PCR, polymerase chain reaction; PML, promyelocytic leukemia; RAR, retinoic acid receptor; FISH, fluorescent in situ hybridization.

Case 2

An 80-year-old man was diagnosed with APL in 2004 at the First Department of Internal Medicine, Kansai Medical University. The patient was administered treatment with ATRA plus IDA, and CR was attained. The patient relapsed in June 2012. A second treatment with ATRA was administered and the patient exhibited a second CR. A second relapse occurred and the patient received ATO, however, this was subsequently discontinued due to QT interval prolongation. Tamibarotene was started, however, the disease was resistant. A bone marrow smear revealed 22% APL cells. The mRNA of PML/RARα was detected by RT-qPCR (8.3×104 copies/µg). The results of laboratory tests were as follows: Erythrocyte count, 2.43×1012/l; platelet count, 10.3×109/l; leukocyte count, 9.0×109/l (the leukocytes included 0% promyelocytes, 1% monocytes, 55% neutrophils and 43% lymphocytes).

GO (9 mg/m2) was administered on day 1. The clinical course is shown in Fig. 2. Although the coagulation profile revealed no presence of DIC prior to the treatment with GO, prominent DIC was transiently observed following the treatment. On day 4, the PT was 77.6%, the APTT was 29.4 sec, the fibrinogen level was 350 g/l, the FDP level was 176.4 µg/ml and the FDP-DD level was elevated to 109 µg/ml. rTM treatment was initiated, and the FDP and FDP-DD level gradually decreased. On day 9, the patient acquired a severe infection, which transiently increased the FDP-DD level. Following recovery from the infection, the FDP-DD level returned to normal. During the treatment course, reduction of the fibrinogen level was not observed. Due to the infection, the patient was unable to receive GO on day 15. Molecular CR was confirmed on day 24.

Figure 2.

Clinical course of the patient in case 2. GO, gemtuzumab ozogamicin; PT, prothrombin time; WBC, white blood cell count; PLT, platelets; rTM, recombinant human soluble thrombomodulin; APTT, activated partial thromboplastin time; FDP, fibrin degradation product; PCR, polymerase chain reaction; PML, promyelocytic leukemia; RAR, retinoic acid receptor; FISH, fluorescent in situ hybridization.

Discussion

GO is a recombinant humanized IgG4 anti-CD33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of APL (1–8), although its efficacy in ATRA- and chemotherapy-resistant fully-relapsed APL remains to be elucidated. Certain basic reasons may explain the effectiveness of GO for the treatment of APL. Firstly, large quantities of CD33 are commonly expressed on the surface of APL cells. Secondly, the levels of P-glycoprotein (a multidrug-resistant glycoprotein) are lower on the surface of APL cells compared with on the surface of acute myeloid leukemia (AML) cells. Thirdly, APL cells are highly sensitive to free calicheamicin, an antitumor antibiotic (2,3).

Several previous studies have hypothesized the efficacy of GO for APL (1,5). In a previous study performed at the MD Anderson Cancer Center (Houston, TX, USA), the CR rate was 81% in high-risk patients who received GO (5). The combination of ATRA and ATO plus GO is now being evaluated in a North American Intergroup APL trial for high-risk APL. Italian investigators noted that early treatment of molecular relapse of APL with single-agent GO resulted in longer survival compared with the initiation of treatment at hematological relapse (1).

The relative rarity of APL, particularly molecular relapse of APL, makes a randomized study to confirm these findings infeasible. The SWOG106 study, comprising a trial of GO with cytarabine plus anthracycline in relapsed AML, found no improvement in event-free survival, disease-free survival or overall survival (11). These results prompted Pfizer to voluntarily withdraw GO from the market in the United States in June 2010, prior to the results of other randomized trials being made available.

A post-marketing study of GO in Japan reported that the frequencies of adverse events were myelosuppression (67%), infusion reaction (47%), liver dysfunction (43%), infection (35%), bleeding (17%) and DIC (7%). Prominent DIC following treatment with GO was reported in two previous cases (9). In that previous study, the investigators assumed that GO may increase the frequency and severity of DIC due to APL cells collapsing rapidly. However, the frequency of DIC in the post-marketing surveillance was 7%, meaning that DIC does not necessarily occur in all cases. If DIC arose through the collapse of APL cells, it may be proportional to the quantity of APL cells. In the present study, case 1 exhibited a molecular relapse, however, the number of APL cells was so small that it could not be counted in the bone marrow smear and blood tests. Therefore, the quantity of tumor cells must have been small, however, DIC still occurred. By contrast, following the treatment with GO on day 15, DIC did not occur. From this clinical course, it can be assumed that DIC must have occurred through a mechanism other than the quantity of APL cells. The present study hypothesized that GO may damage vascular endothelial cells and cause DIC, since GO is said to be associated with the development of sinusoidal obstruction. The mechanism of sinusoidal obstruction caused by GO remains unclear, however, it may be similar to DIC. Since the initial onset of DIC and sinusoidal obstruction is vascular endothelial damage, it was assumed that rTM may prevent DIC from occurring in the administration of 15 days of GO. The present study initiated rTM on day 4, which was soon after DIC occurred and continued it until day 11, then administered GO on day 15. The present study hypothesized that the effects of rTM remained on day 15 and assisted with the treatment of endothelial damage, therefore, the increase of FDP-DD was less than on day 1.

APL is characterized by fibrinolytic-type DIC, which is characterized by increasing levels of FDP-DD and decreasing levels of fibrinogen. rTM was approved for treatment of DIC in Japan in 2008. Previously, heparin and gabexate mesilate were used prophylactically prior to the treatment with GO (9). In the present study, rTM was used for the first time, to the best of our knowledge, for DIC triggered by GO. Although a report indicated that rTM was effective in the treatment with ATRA or ATO for DIC (12), its usefulness for treatment of APL has not been confirmed in larger studies. No bleeding-associated mortality was noted during induction chemotherapy in APL patients who received rTM (13). Notably, severe hemorrhage requiring red blood cell transfusion at the time of diagnosis of APL was reduced following the initiation of rTM (14). Use of rTM in combination with ATO for relapse of APL promptly improved DIC without any adverse effects in one previous case report (15). An in vitro study demonstrated that exposure of APL cells to rTM significantly downregulated the level of annexin II, resulting in a decrease in plasmin production (16). However, the mechanism remains to be elucidated in vivo.

rTM was stopped after 7 days, since its safety for use over 7 days remains to be determined. In the present case, following treatment with rTM, the efficacy of rTM remained and FDP-DD kept decreasing.

Each of the cases in the present study achieved early molecular CR following treatment with GO. Therefore, GO may be a promising agent for the management of APL and may become one of the treatment options for recurrent APL in elderly patients. Since DIC is the most serious adverse event of GO treatment, elucidation of its mechanism and establishment of a treatment strategy are warranted.